This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
by Zacks Equity Research
RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
by Zacks Equity Research
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
by Ekta Bagri
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
by Zacks Equity Research
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
by Zacks Equity Research
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
by Zacks Equity Research
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
by Zacks Equity Research
Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.
Intellia Focuses on Pipeline Development Amid Stiff Competition
by Zacks Equity Research
Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
by Urmimala Biswas
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.
Top Stock Reports for Tesla, Home Depot & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, Inc. (HD) and Boston Scientific Corp. (BSX), as well as two micro-cap stocks Frequency Electronics, Inc. (FEIM) and Bridger Aerospace Group Holdings, Inc. (BAER).
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
by Zacks Equity Research
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
by Zacks Equity Research
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
by Zacks Equity Research
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TSVT Up on Acquisition Agreement With BMY for $286 Million
by Zacks Equity Research
2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
by Zacks Equity Research
Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
by Zacks Equity Research
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
by Zacks Equity Research
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.